Isabella Visuri

6PUBLICATIONS
10CO-AUTHORS
Immunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Disease surveillancePredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 28, 2025
Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH study.

Linda Ryen, Isabella Visuri, Sara Karlqvist

|Oct 26, 2023
Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels.

Joel Thunberg, Olle Grännö, Daniel Bergemalm

|Jun 05, 2023
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study.

Isabella Visuri, Carl Eriksson, Sara Karlqvist

|Aug 23, 2021
Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.

Isabella Visuri, Carl Eriksson, Ola Olén

|Aug 20, 2021
Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.

Carl Eriksson, Isabella Visuri, Lina Vigren

|Jul 21, 2021
Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.

Isabella Visuri, Carl Eriksson, Ola Olén

Pageof 1

Frequent Collaborators

6 joint publications

Carl Eriksson

2 joint publications

Pär Myrelid

2 joint publications

Jonas F Ludvigsson

2 joint publications

Sven Almer